NETs Biomarkers in Saliva and Serum OSCC Patients: One Hypothesis, Two Conclusions
Overview
Authors
Affiliations
Purpose: The actual role of neutrophils and neutrophil extracellular traps (NETs) in the course of cancer has not been clearly defined. The aim of this study was to determine the clinical usefulness of NETs biomarkers in saliva in confrontation with the blood serum and tumor tissue as a potential prognostic and therapeutic target in patients with oral squamous cell carcinoma (OSCC).
Material And Methods: Expression of myeloperoxidase (MPO), and histones H2A, H2B, H3 in the tumor tissue, was investigated using immunohistochemistry. The expression of nicotinamide adenine dinucleotide phosphate (NADPH) oxidase subunits: p47-phox, p67-phox (neutrophil cytosolic factor 2, NCF2) and panRac, as well as citrullinated histone H3 (CitH3) in peripheral blood neutrophil lysates, was assessed via Western blot. ELISA tests were employed to measure the concentrations of circulating free DNA (cfDNA) and MPO in saliva only, and NOX1, NCF2, DNASE1 in saliva and serum.
Results: Extracellular expression of MPO and histones was localized within tumor tissue. Significantly lower expression of p67-phox, panRac, and CitH3 was determined in OSCC patients. Considerably lower concentrations of NOX1, NCF2, and DNASE1 in the saliva samples of cancer patients were observed. However, the levels of NOX1, NCF2, and DNASE1 in the serum of patients with cancer were substantially higher.
Conclusions: The results obtained from the saliva of cancer patients suggest an impairment of the immunological homeostasis within the oral cavity related to NET formation, the causes of which should be sought in deficient activation of NADPH oxidase.
Local Drug Delivery Systems as Novel Approach for Controlling NETosis in Periodontitis.
Bosca A, Dinte E, Mihu C, Parvu A, Melincovici C, Sovrea A Pharmaceutics. 2024; 16(9).
PMID: 39339210 PMC: 11435281. DOI: 10.3390/pharmaceutics16091175.
Neutrophils in HNSCC Can Be Associated with Both a Worse or Favorable Prognosis.
Brunkhorst H, Schnellhardt S, Buttner-Herold M, Daniel C, Fietkau R, Distel L Biomolecules. 2024; 14(2).
PMID: 38397442 PMC: 10886850. DOI: 10.3390/biom14020205.
Kallo G, Bertalan P, Marton I, Kiss C, Csosz E Int J Mol Sci. 2023; 24(17).
PMID: 37686462 PMC: 10487546. DOI: 10.3390/ijms241713657.
Low serum level of citrullinated histone H3 in patients with dermatomyositis.
Wang W, Peng W, Wu S J Clin Lab Anal. 2023; 37(6):e24876.
PMID: 37003600 PMC: 10156100. DOI: 10.1002/jcla.24876.
Garley M Cancer Control. 2023; 30:10732748231159313.
PMID: 36814071 PMC: 9950614. DOI: 10.1177/10732748231159313.